Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chennan Li

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Research Square|February 12, 2026
Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancerAdam Sowalsky, Chennan Li, Anna Baj, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
NPJ Precision Oncology|April 9, 2026
Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
Journal of Ethnopharmacology|June 22, 2024
Wutou decoction alleviates arthritis inflammation in CIA mice by regulating Treg cell stability and Treg/Th17 balance via the JAK2/STAT3 pathwayLiang Han, Jiahui Yan, Tingting Li, et al.
European Urology|May 22, 2025
Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate CancerWoonghee Lee, Joon-Yong Chung, Kwamena E Baidoo, et al.
The Prostate|May 6, 2024
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasisJuanJuan Yin, Asha Daryanani, Fan Lu, et al.
Cancer Research|January 13, 2026
MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate CancerSurendra Gulla, Tej Sharma, Ephraim Gardner, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Research Square|February 12, 2026
Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancerAdam Sowalsky, Chennan Li, Anna Baj, et al.
Medrxiv : the Preprint Server for Health Sciences|January 16, 2026
Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
NPJ Precision Oncology|April 9, 2026
Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancerChennan Li, JuanJuan Yin, Melissa L Abel, et al.
Journal of Ethnopharmacology|June 22, 2024
Wutou decoction alleviates arthritis inflammation in CIA mice by regulating Treg cell stability and Treg/Th17 balance via the JAK2/STAT3 pathwayLiang Han, Jiahui Yan, Tingting Li, et al.
European Urology|May 22, 2025
Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate CancerWoonghee Lee, Joon-Yong Chung, Kwamena E Baidoo, et al.
The Prostate|May 6, 2024
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasisJuanJuan Yin, Asha Daryanani, Fan Lu, et al.
Cancer Research|January 13, 2026
MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate CancerSurendra Gulla, Tej Sharma, Ephraim Gardner, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Pageof 2